Fundraising Fox
/Companies
Sign in

Tarsus Pharmaceuticals

NASDAQ: TARS

Founded 2017 · Incorporated in Delaware · 440 employees on LinkedIn · 7 known investors

Find your way into Tarsus Pharmaceuticals

Sign up to see every warm intro you have to Tarsus Pharmaceuticals

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Tarsus Pharmaceuticals team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Tarsus is a biopharmaceutical company focused on developing and delivering medicines that target the root cause of serious diseases with high unmet need, including eye conditions. Its treatment areas include Demodex blepharitis, and it works closely with eye care professionals and patients.

BiotechHealthtechMedical Devices

Founders & leadership

Tarsus Pharmaceuticals was founded in 2017 by Bobak Azamian.

BABobak Azamian
Bobak AzamianFounder · ChairmanBobak Azamian, an MD and PhD trained physician and scientist, co-founded Tarsus Pharmaceuticals in 2016 and serves as its Chairman and CEO. The company develops treatments for diseases with high unmet need and launched XDEMVY, an FDA-approved therapy for Demodex blepharitis, while advancing a pipeline spanning conditions such as ocular rosacea and Lyme disease prevention.
JF
Jeffrey FarrowChief Financial Officer and Chief Strategy Officer
SN
Seshadri NeervannanChief Operating Officer
AMAziz Mottiwala
Aziz MottiwalaChief Commercial Officer2020–2026Aziz Mottiwala is a healthcare executive with over 25 years of commercialization experience, including nearly 20 years in eye care across roles at Allergan (VP of Marketing, Eye Care Franchise), Opiant, Avanir, Valeant, and other pharmaceutical companies; he holds a BS in Biochemistry from UC San Diego and an MBA in Marketing and Finance from USC Marshall.
DWDianne Whitfield
Dianne WhitfieldChief Human Resources OfficerDianne Whitfield is Chief Human Resources Officer at Tarsus Pharmaceuticals, a biopharmaceutical company developing treatments for serious diseases with high unmet need including eye conditions. She brings decades of experience in talent management, organizational effectiveness, leadership development, and strategic business partnership.
EYElizabeth Yeu-Lin
Elizabeth Yeu-LinChief Medical Officer

Investors · 7

Flying L Partnerslisted by Flying L Partners

How we know: Flying L Partners's portfolio page · Not right? Tell us

Frazier Life Scienceslisted by Frazier Life SciencesPalo Alto

How we know: Frazier Life Sciences's portfolio page · the S-1 prospectus · open dataset · 5k.vc investor directory · Not right? Tell us

Visionary Ventureslisted by Visionary VenturesNewport Beach · $5M – $15M
Vivo Capitallisted by Vivo CapitalPalo Alto · $10M – $50M

How we know: Vivo Capital's portfolio page · the S-1 prospectus · open dataset · 5k.vc investor directory · Not right? Tell us

Bain Capital Life SciencesreportedBoston

How we know: funding news · Not right? Tell us

RTW Investments L.P.reportedNew York

How we know: the S-1 prospectus · funding news · Not right? Tell us

Funding

SEC filings, press & company announcements

$125M disclosed across 1 of 3 rounds · 2019–2026

  • $125MPIPE financingAug 2026 · 2 sources
    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Valuation · disclosed

Disclosed events
$311.9Mvaluation at IPOOct 2020 · $16.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Frequently asked questions

What does Tarsus Pharmaceuticals do?
Tarsus is a biopharmaceutical company focused on developing and delivering medicines that target the root cause of serious diseases with high unmet need, including eye conditions. Its treatment areas include Demodex blepharitis, and it works closely with eye care professionals and patients.
Who founded Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals was founded by Bobak Azamian in 2017.
Who are Tarsus Pharmaceuticals's investors?
Tarsus Pharmaceuticals's investors include APERTURE Venture Partners, Flying L Partners, Frazier Life Sciences, Visionary Ventures, Vivo Capital, Bain Capital Life Sciences, RTW Investments L.P..
How much funding has Tarsus Pharmaceuticals raised?
Tarsus Pharmaceuticals has disclosed $125M raised across 1 of its 3 known rounds.